

Freedom of Information Request - FOI2024/076

21 May 2024

Thank you for your Freedom of Information request.

We are analysing the usage of biologic and biosimilar products within Rheumatology and it would be really helpful if you could please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]

I have considered your request and have set out the Trust's response below:

Drug	Patients
Abatacept [Orencia]	34
Adalimumab [Humira]	25
Adalimumab Biosimilars	306
Apremilast [Otezla]	7
Baricitinib [Olumiant]	24
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	62
Etanercept [Enbrel]	18
Etanercept Biosimilars	130

Filgotinib [Jyseleca]	7
Golimumab [Simponi]	7
Guselkumab [Tremfya]	0
Infliximab [Remicade]	Less than 6*
Infliximab Biosimilars	17
Ixekizumab [Taltz]	13
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	Less than 6*
Rituximab Biosimilars	59
Sarilumab [Kevzara]	Less than 6*
Secukinumab [Cosentyx]	88
Tocilizumab [Ro Actemra]	53
Tocilizumab Biosimilars	0
Tofacitinib [Xeljanz]	Less than 6*
Upadacitinib [Rinvoq]	15
Ustekinumab [Stelara]	Less than 6*

* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,

Freedom of Information Officer